|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edwards BK, Brown ML, Wingo PA, Howe HL,
Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, et al:
Annual report to the nation on the status of cancer, 1975–2002,
featuring population-based trends in cancer treatment. J Natl
Cancer Inst. 97:1407–1427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riall TS, Nealon WH, Goodwin JS, Zhang D,
Kuo YF, Townsend CM Jr and Freeman JL: Pancreatic cancer in the
general population: Improvements in survival over the last decade.
J Gastrointest Surg. 10:1212–1223; discussion 1223–4. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al;
National Cancer Institute of Canada Clinical Trials Group.
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hertzer KM, Donald GW and Hines OJ: CXCR2:
A target for pancreatic cancer treatment? Expert Opin Ther Targets.
17:667–680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pham NA, Schwock J, Iakovlev V, Pond G,
Hedley DW and Tsao MS: Immunohistochemical analysis of changes in
signaling pathway activation downstream of growth factor receptors
in pancreatic duct cell carcinogenesis. BMC Cancer. 8:432008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holmes WE, Lee J, Kuang WJ, Rice GC and
Wood WI: Structure and functional expression of a human
interleukin-8 receptor. Science. 253:1278–1280. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murphy PM and Tiffany HL: Cloning of
complementary DNA encoding a functional human interleukin-8
receptor. Science. 253:1280–1283. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh JK, Simões BM, Howell SJ, Farnie G
and Clarke RB: Recent advances reveal IL-8 signaling as a potential
key to targeting breast cancer stem cells. Breast Cancer Res.
15:2102013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gabellini C, Trisciuoglio D, Desideri M,
Candiloro A, Ragazzoni Y, Orlandi A, Zupi G and Del Bufalo D:
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human
malignant melanoma progression. Eur J Cancer. 45:2618–2627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen T, Yang Z, Cheng X, Xiao Y, Yu K, Cai
X, Xia C and Li Y: CXCL8 induces epithelial-mesenchymal transition
in colon cancer cells via the PI3K/Akt/NF-κB signaling pathway.
Oncol Rep. 37:2095–2100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brandolini L, Cristiano L, Fidoamore A, De
Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque
B, Benedetti E, et al: Targeting CXCR1 on breast cancer stem cells:
Signaling pathways and clinical application modelling. Oncotarget.
6:43375–43394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T,
Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chapman RW, Minnicozzi M, Celly CS,
Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R,
et al: A novel, orally active CXCR1/2 receptor antagonist,
Sch527123, inhibits neutrophil recruitment, mucus production, and
goblet cell hyperplasia in animal models of pulmonary inflammation.
J Pharmacol Exp Ther. 322:486–493. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bertini R, Allegretti M, Bizzarri C,
Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V,
Cesta MC, Galliera E, et al: Noncompetitive allosteric inhibitors
of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention
of reperfusion injury. Proc Natl Acad Sci USA. 101:11791–11796.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Opfermann P, Derhaschnig U, Felli A,
Wenisch J, Santer D, Zuckermann A, Dworschak M, Jilma B and
Steinlechner B: A pilot study on reparixin, a CXCR1/2 antagonist,
to assess safety and efficacy in attenuating ischaemia-reperfusion
injury and inflammation after on-pump coronary artery bypass graft
surgery. Clin Exp Immunol. 180:131–142. 2015. View Article : Google Scholar :
|
|
20
|
Schott AF, Goldstein LJ, Cristofanilli M,
Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G and Wicha M:
Phase ib pilot study to evaluate reparixin in combination with
weekly paclitaxel in patients with HER-2-Negative metastatic breast
cancer. Clin Cancer Res. 23:5358–5365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ginestier C, Liu S, Diebel ME, Korkaya H,
Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum
D, et al: CXCR1 blockade selectively targets human breast cancer
stem cells in vitro and in xenografts. J Clin Invest. 120:485–497.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singh S, Sadanandam A, Nannuru KC, Varney
ML, Mayer-Ezell R, Bond R and Singh RK: Small-molecule antagonists
for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing
tumor cell proliferation, survival, and angiogenesis. Clin Cancer
Res. 15:2380–2386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Liu J, Jiang Q, Deng J, Xu F, Chen
X, Cheng F, Zhang Y, Yao Y, Xia Z, et al: Human adipose-derived
mesenchymal stem cell-secreted CXCL1 and CXCL8 facilitate breast
tumor growth by promoting angiogenesis. Stem Cells. 35:2060–2070.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ning Y, Labonte MJ, Zhang W, Bohanes PO,
Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli
Venkata KC, et al: The CXCR2 antagonist, SCH-527123, shows
antitumor activity and sensitizes cells to oxaliplatin in
preclinical colon cancer models. Mol Cancer Ther. 11:1353–1364.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nair P, Gaga M, Zervas E, Alagha K,
Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J and Chanez P;
Study Investigators: Safety and efficacy of a CXCR2 antagonist in
patients with severe asthma and sputum neutrophils: A randomized,
placebo-controlled clinical trial. Clin Exp Allergy. 42:1097–1103.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuwada Y, Sasaki T, Morinaka K, Kitadai Y,
Mukaida N and Chayama K: Potential involvement of IL-8 and its
receptors in the invasiveness of pancreatic cancer cells. Int J
Oncol. 22:765–771. 2003.PubMed/NCBI
|
|
27
|
Takamori H, Oades ZG, Hoch OC, Burger M
and Schraufstatter IU: Autocrine growth effect of IL-8 and GROalpha
on a human pancreatic cancer cell line, Capan-1. Pancreas.
21:52–56. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyamoto M, Shimizu Y, Okada K, Kashii Y,
Higuchi K and Watanabe A: Effect of interleukin-8 on production of
tumor-associated substances and autocrine growth of human liver and
pancreatic cancer cells. Cancer Immunol Immunother. 47:47–57. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Wang Y, Dong S, Ge C, Xiao Y, Li R,
Ma X, Xue Y, Zhang Q, Lv J, et al: Association of CXCR1 and 2
expressions with gastric cancer metastasis in ex vivo and tumor
cell invasion in vitro. Cytokine. 69:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jayatilaka H, Tyle P, Chen JJ, Kwak M, Ju
J, Kim HJ, Lee JSH, Wu PH, Gilkes DM, Fan R, et al: Synergistic
IL-6 and IL-8 paracrine signalling pathway infers a strategy to
inhibit tumour cell migration. Nat Commun. 8:155842017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Knall C, Worthen GS and Johnson GL:
Interleukin 8-stimulated phosphatidylinositol-3-kinase activity
regulates the migration of human neutrophils independent of
extracellular signal-regulated kinase and p38 mitogen-activated
protein kinases. Proc Natl Acad Sci USA. 94:3052–3057. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smalley KS: A pivotal role for ERK in the
oncogenic behaviour of malignant melanoma? Int J Cancer.
104:527–532. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Venkatakrishnan G, Salgia R and Groopman
JE: Chemokine receptors CXCR-1/2 activate mitogen-activated protein
kinase via the epidermal growth factor receptor in ovarian cancer
cells. J Biol Chem. 275:6868–6875. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Palmer AA, Zhang XD, Thompson JF, Bron LP and Hersey P: Activation
of the extracellular signal regulated kinase (ERK) pathway in human
melanoma. J Clin Pathol. 58:1163–1169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burger M, Hartmann T, Burger JA and
Schraufstatter I: KSHV-GPCR and CXCR2 transforming capacity and
angiogenic responses are mediated through a JAK2-STAT3-dependent
pathway. Oncogene. 24:2067–2075. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu B, Lin N, Zhang M, Zhu Y, Cheng H,
Chen S, Ling Y, Pan W and Xu R: Activated hepatic stellate cells
promote angiogenesis via interleukin-8 in hepatocellular carcinoma.
J Transl Med. 13:3652015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
MacManus CF, Pettigrew J, Seaton A, Wilson
C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG and
Waugh DJ: Interleukin-8 signaling promotes translational regulation
of cyclin D in androgen-independent prostate cancer cells. Mol
Cancer Res. 5:737–748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nandagopal N and Roux PP: Regulation of
global and specific mRNA translation by the mTOR signaling pathway.
Transl Austin. 3:e9834022015.
|
|
39
|
Chen L, Fan J, Chen H, Meng Z, Chen Z,
Wang P and Liu L: The IL-8/CXCR1 axis is associated with cancer
stem cell-like properties and correlates with clinical prognosis in
human pancreatic cancer cases. Sci Rep. 4:59112014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Holz O, Khalilieh S, Ludwig-Sengpiel A,
Watz H, Stryszak P, Soni P, Tsai M, Sadeh J and Magnussen H:
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced
neutrophilia in healthy subjects. Eur Respir J. 35:564–570. 2010.
View Article : Google Scholar
|
|
41
|
Bi LK, Zhou N, Liu C, Lu FD, Lin TX, Xuan
XJ, Jiang C, Han JL, Huang H, Zhang CX, et al: Kidney cancer cells
secrete IL-8 to activate Akt and promote migration of mesenchymal
stem cells. Urol Oncol. 32:607–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX,
Chen S, Chen ZY, Xiang YQ, Bao YN, Zheng FJ, et al: As an
independent unfavorable prognostic factor, IL-8 promotes metastasis
of nasopharyngeal carcinoma through induction of
epithelial-mesenchymal transition and activation of AKT signaling.
Carcinogenesis. 33:1302–1309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luppi F, Longo AM, de Boer WI, Rabe KF and
Hiemstra PS: Interleukin-8 stimulates cell proliferation in
non-small cell lung cancer through epidermal growth factor receptor
transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar
|
|
44
|
Scholz A, Heinze S, Detjen KM, Peters M,
Welzel M, Hauff P, Schirner M, Wiedenmann B and Rosewicz S:
Activated signal transducer and activator of transcription 3
(STAT3) supports the malignant phenotype of human pancreatic
cancer. Gastroenterology. 125:891–905. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Magnuson B, Ekim B and Fingar DC:
Regulation and function of ribosomal protein S6 kinase (S6K) within
mTOR signalling networks. Biochem J. 441:1–21. 2012. View Article : Google Scholar
|
